Clinical trial

Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy

NCT03027245

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2016-10-13

PhaseN/A

Study timeline

Study start (actual)2016-10-13Date precision: day

Registry last updated2022-07-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Locally Advanced or Metastatic Breast Cancerunresolved

Interventions

EribulinDRUG · verified · RxNorm: eribulin

Sponsors & collaborators

Eisai GmbHlead sponsor

Mapped research locations

BerlinGermany3 MünchenGermany3 HanoverGermany2 CologneGermany2 BonnGermany2 DresdenGermany1 EssenGermany1 MainzGermany1 MünsterGermany1 TübingenGermany1 Freiburg im BreisgauGermany1 MannheimGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03027245 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.